These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12172588)

  • 21. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 22. Medicaid program; premiums and cost sharing. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Nov; 73(228):71827-55. PubMed ID: 19143111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How complete are drug history profiles that are based on public drug benefit claims?
    Paterson JM; Suleiman A; Hux JE; Bell C
    Can J Clin Pharmacol; 2008; 15(1):e108-16. PubMed ID: 18283220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of health insurance coverage in women's access to prescription medicines.
    Ranji UR; Wyn R; Salganicoff A; Yu H
    Womens Health Issues; 2007; 17(6):360-6. PubMed ID: 18042485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public preferences and organized interests in health policy: state pharmacy assistance programs as innovations.
    Gray V; Lowery D; Godwin EK
    J Health Polit Policy Law; 2007 Feb; 32(1):89-129. PubMed ID: 17312326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.
    Mintzes B; Barer M; Lexchin J; Bassett KL
    Res Social Adm Pharm; 2005 Jun; 1(2):310-30. PubMed ID: 17138480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicaid: Medicaid: eligibility--2005. End of Year Issue Brief.
    Johnson P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-15. PubMed ID: 16710917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future and long-range planning of healthcare services: a Saskatchewan perspective.
    Adams D
    World Hosp Health Serv; 1994; 30(1):25-31. PubMed ID: 10135091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicare Program; revisions to the Medicare Advantage and Prescription Drug Benefit programs. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Sep; 73(182):54225-54. PubMed ID: 18985953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validity of self-reported prescription drug insurance coverage.
    Grootendorst P; Newman EC; Levine MA
    Health Rep; 2003 Feb; 14(2):35-46. PubMed ID: 12658863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease.
    Stuart B; Doshi JA; Briesacher B; Wrobel MV; Baysac F
    Clin Ther; 2004 Oct; 26(10):1688-99. PubMed ID: 15598486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for acquiring affordable medications for seniors.
    Morris KJ
    Nurs Clin North Am; 2005 Mar; 40(1):51-62, vi. PubMed ID: 15733946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicare Part D subsidies. Final rules.
    Social Security Administration (SSA)
    Fed Regist; 2005 Dec; 70(250):77663-85. PubMed ID: 16392171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caught in between: prescription drug coverage of Medicare beneficiaries near poverty.
    Shea DG; Stuart BC; Briesacher B
    Issue Brief (Commonw Fund); 2003 Aug; (669):1-8. PubMed ID: 12926411
    [No Abstract]   [Full Text] [Related]  

  • 37. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.
    Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
    Circulation; 2007 Apr; 115(16):2128-35. PubMed ID: 17420348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lessons for Medicare Part D in the hemodialysis community.
    Nayeem AI; Chertow GM
    BMC Nephrol; 2006 Jul; 7():11. PubMed ID: 16824211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whither seniors' pharmacare: lessons from (and for) Canada.
    Morgan SG; Barer ML; Agnew JD
    Health Aff (Millwood); 2003; 22(3):49-59. PubMed ID: 12757272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.